Liraglutide vs Tripeptide-29
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideSkin & CosmeticAnti-Aging & Longevity
Tripeptide-29- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
- Half-Life
- ~13 hours (once-daily dosing)
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 0.01-0.1% in formulation
- Frequency
- Once daily
- Once or twice daily
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Stimulates fibroblast collagen synthesis via damage-signal mechanism
- Reduces fine lines and improves skin smoothness
- Supports dermal matrix integrity
- Naturally bioidentical to collagen fragment sequences
- Well-tolerated in all skin types
- Synergistic with copper peptides and retinoids
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Excellent tolerability profile
- No documented significant adverse effects at cosmetic concentrations
- Rare sensitivity reactions in individuals with peptide allergies
- Stacks With
- —
- —